Skip to main content
    M

    MoonLake Immunotherapeutics (MLTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.25
    -0.48 (-4.09%)

    Market Cap: $1.06B

    Last updated: Nov 17, 2026 at 4:24 PM ET

    MoonLake Immunotherapeutics (MLTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    MoonLake Immunotherapeutics (MLTX) has a market cap of $1.06B and an enterprise value of $784.14M. Its share count is up 34.73% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 26.29% below the market cap, as cash exceeds debt.

    Market Cap$1.06B
    Enterprise Value$784.14M
    Latest price (Nov 17, 2026)$11.25

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 42.24% in the quarter ended Sep 30, 2026 and grew 16.51% a year over 2 years.

    Shares Outstanding85.38M
    Shares Change (YoY)+34.73%
    Shares Change (QoQ)-42.24%
    Share Count Growth (2Y CAGR)+16.51%

    Price Statistics

    The stock is down 11.90% over 52 weeks and trades 4.17% below its 50-day average.

    Beta (1Y)1.62
    52-Week Change-11.90%
    1-Month Change+15.38%
    3-Month Change-32.80%
    6-Month Change-31.28%
    5-Year Change+17.80%
    Total Return (1Y)-11.90%
    Total Return (3Y CAGR)-35.91%
    Total Return (5Y CAGR)+2.55%
    Return vs SPY (1Y)-27.60%
    Max Drawdown (1Y)-56.90%
    Max Drawdown (3Y)-90.22%
    Sharpe Ratio (1Y)-0.25
    Correlation with SPY (1Y)0.31
    50-Day Average$11.74
    200-Day Average$16.22
    52-Week Range$9.46 to $23.29
    RSI (14 Days)44.8
    Average Volume (20 Days)1.66M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 9.13x current liabilities, and total debt is 0.26x shareholder equity.

    Current Ratio9.13x
    Quick Ratio9.13x
    Debt / Equity0.26x
    Interest Coverage-27.53x

    Returns and Efficiency

    Return on invested capital is -54.59% over the last 12 months, against a 5-year average of -58.76%.

    Return on Equity (ROE)-71.82%
    Return on Assets (ROA)-50.69%
    Return on Invested Capital (ROIC)-54.59%
    Return on Capital Employed (ROCE)-54.52%
    ROA (5Y Average)-43.77%
    ROIC (5Y Average)-58.76%

    Scores

    MLTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$751.00K
    Operating Income-$276.75M
    Pretax Income-$272.48M
    Net Income-$274.07M
    EBITDA-$259.54M
    EBIT-$262.93M
    Reported EPS (TTM)-$3.67

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 70.58% of the $540.72M in total assets.

    Cash and Equivalents$379.70M
    Total Debt$100.01M
    Net Cash$279.69M
    Net Cash Per Share$3.28
    Working Capital$474.91M
    Shareholder Equity$381.63M
    Book Value Per Share$4.47
    Total Assets$540.72M
    Total Liabilities$159.09M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$244.04M
    FCF Per Share-$2.87
    Depreciation and Amortization$3.40M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-24.44%
    Tangible Book Per Share Growth (2Y CAGR)-24.44%

    Revenue and profit by year

    Dividends and Yields

    MLTX does not pay a dividend.

    Buyback Yield-15.74%
    Shareholder Yield-15.74%

    Peer Position

    Against 7 similar companies, MLTX has the 7th highest ROIC.

    ROIC-54.59% vs -14.91% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -8.87% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About MLTX

    What is MLTX's market cap?

    MoonLake Immunotherapeutics has a market cap of $1.06B. Its enterprise value, which adds debt and subtracts cash, is $784.14M.

    How many shares of MLTX are outstanding?

    MoonLake Immunotherapeutics has 85.38M shares outstanding. The count is up 34.73% from a year earlier.

    Does MLTX pay a dividend?

    No. MoonLake Immunotherapeutics does not pay a dividend.

    How much debt does MLTX have?

    MoonLake Immunotherapeutics has $100.01M of total debt and $379.70M of cash and equivalents, a net cash position of $279.69M.